Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Preferred Stock Liabilities: 2014-2023

Historic Preferred Stock Liabilities for Spyre Therapeutics (SYRE) over the last 3 years, with Dec 2023 value amounting to $84.6 million.

  • Spyre Therapeutics' Preferred Stock Liabilities was N/A to $253.4 million in Q1 2024 from the same period last year, while for Mar 2024 it was $253.4 million, marking a year-over-year change of. This contributed to the annual value of $84.6 million for FY2023, which is N/A change from last year.
  • As of FY2023, Spyre Therapeutics' Preferred Stock Liabilities stood at $84.6 million, which was up 89.00% from $44.7 million recorded in FY2015.
  • Spyre Therapeutics' 5-year Preferred Stock Liabilities high stood at $84.6 million for FY2023, and its period low was $84.6 million during FY2023.
  • Its 1-year average for Preferred Stock Liabilities is $84.6 million, with a median of $84.6 million in 2023.